L-arginine Reduces COVID-19 in-Hospital stay

L-arginine taken twice a day by COVID-19 patients leads to reduced in-hospital stay lessening the need for a ventilator, a study finds. Randomized clinical trials found that patients who took the therapy were less likely to require respiratory support compared to those who didn’t.

Chronic inflammation is often a result of endothelial dysfunction and according to several journals, is fundamental in long-COVID. This is clearly a result of oxidative stress which occurs when there is an imbalance between free radicals and anti oxidants. Increasing L-arginine bioavailability with supplementation can therefore increase T-cell response and function. An increase in the Th17 cells however are ‘implied in the pathogenesis of the cytokine storm’, the article states. It is this that causes hyperinflammation as higher L-arginine levels can reduce CCL-20, the inflammatory cytokine protein responsible.

This news should be of little surprise to those who regularly use the L-arginine Plus food supplement. One of its best known benefits was always at the cellular level in particular the endothelial lining of the blood cells. L-arginine converts to nitric oxide relaxing the blood cells, reducing the stress on the heart and improving circulation. It provides the body’s major source for nitric oxide synthesis without which human life is not possible. L-arginine significantly reduces high blood pressure. Reducing COVID-19 in-hospital stay duration must always be a primary objective.